ES2550003T3 - Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones - Google Patents

Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones Download PDF

Info

Publication number
ES2550003T3
ES2550003T3 ES09806538.6T ES09806538T ES2550003T3 ES 2550003 T3 ES2550003 T3 ES 2550003T3 ES 09806538 T ES09806538 T ES 09806538T ES 2550003 T3 ES2550003 T3 ES 2550003T3
Authority
ES
Spain
Prior art keywords
fosaprepitant
dimeglumine
preparations
neutral
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09806538.6T
Other languages
English (en)
Other versions
ES2550003T5 (es
Inventor
Navin Ganeshbhatt
Nikhil Rasiklaltrivedi
Mahesh Khedekar
Sukumar Sinha
Mubeen Ahmed Khan
Ramjilal Yadav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glenmark Generics Ltd
Original Assignee
Glenmark Generics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2550003(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Generics Ltd filed Critical Glenmark Generics Ltd
Application granted granted Critical
Publication of ES2550003T3 publication Critical patent/ES2550003T3/es
Publication of ES2550003T5 publication Critical patent/ES2550003T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un proceso para la preparación de una forma cristalina de ácido dibencil {3-[2(R)-[(1R)-1-[3,5- bis(trifluorometil)fenil]etoxi]-3(S)-(4-fluorofenil)morfolin-4-il}-5-oxo-4,5-dihidro-[1,2,4]-triazol-1-il}fosfónico de fórmula (II),**Fórmula** y el proceso comprende: (a) proporcionar una solución de ácido dibencil {3-[2(R)-[(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi]-3(S)-(4- fluorofenil)morfolin-4-il}-5-oxo-4,5-dihidro-[1,2,4]-triazolil}fosfónico en un solvente o una mezcla de solventes; (b) adicionar un anti-solvente a la solución del paso (a) para hacer precipitar un sólido; y (c) recuperar la forma cristalina de ácido dibencil{3-[2(R)-[(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi]-3(S)-(4- fluorofenil)morfolin-4-il}-5-oxo-4,5-dihidro-[1,2,4]-triazol-1-il}fosfónico como un precipitado, en cuyo caso la precipitación se lleva a cabo a un rango de temperaturas desde -10 °C a 35 °C.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
    imagen2
ES09806538.6T 2008-07-17 2009-07-17 Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones Active ES2550003T5 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
INMU15102008 2008-07-17
IN1510MU2008 2008-07-17
INMU21542008 2008-10-08
IN2154MU2008 2008-10-08
IN690MU2009 2009-03-24
INMU06902009 2009-03-24
PCT/IN2009/000408 WO2010018595A2 (en) 2008-07-17 2009-07-17 Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations

Publications (2)

Publication Number Publication Date
ES2550003T3 true ES2550003T3 (es) 2015-11-03
ES2550003T5 ES2550003T5 (es) 2018-08-22

Family

ID=41669418

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09806538.6T Active ES2550003T5 (es) 2008-07-17 2009-07-17 Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones

Country Status (5)

Country Link
US (1) US8623844B2 (es)
EP (1) EP2303901B2 (es)
CA (1) CA2730681C (es)
ES (1) ES2550003T5 (es)
WO (1) WO2010018595A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011045817A2 (en) 2009-10-15 2011-04-21 Sandoz Private Limited Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof
CN102166199B (zh) * 2011-04-02 2012-11-07 武汉希熙生物科技有限公司 一种注射用福沙吡坦二甲葡胺冻干制剂的制备方法
IN2011CH01927A (es) 2011-06-03 2015-10-02 Hetero Research Foundation
CN102977142B (zh) * 2011-09-02 2017-03-29 江苏豪森药业集团有限公司 福沙匹坦二甲葡胺的制备方法
CN103183708A (zh) * 2011-12-31 2013-07-03 扬子江药业集团上海海尼药业有限公司 福沙吡坦二甲葡胺的制备方法
WO2013168176A2 (en) * 2012-03-30 2013-11-14 Glenmark Generics Limited Process for preparation of fosaprepitant and salt thereof
CZ304982B6 (cs) * 2012-04-30 2015-03-11 Zentiva, K.S. Způsob přípravy a čištění nových polymorfů intermediátu fosaprepitantu
CN102675369B (zh) * 2012-05-16 2017-07-11 北京华众思康医药技术有限公司 一种制备[3‑[(2r)‑[(1r)‑1‑[3，5‑二(三氟甲基)苯基]乙氧基]‑3(s)‑(4‑氟苯基)吗啉‑4‑基]甲基]‑5‑氧代‑4，5‑二氢‑[1，2，4]‑三唑‑1‑基]膦酸一苄酯的新方法
US9850267B2 (en) 2015-06-03 2017-12-26 Navinta, Llc Crystalline fosaprepitant dicyclohexylamine salt and its preparation
US10610532B2 (en) 2015-08-03 2020-04-07 Leiutis Pharmaceuticals Pvt. Ltd. Liquid formulations of fosaprepitant
US10428097B2 (en) 2015-12-01 2019-10-01 Piramal Enterprises Limited Process for preparation of fosaprepitant dimeglumine and an intermediate thereof
CN107353303B (zh) * 2016-05-09 2020-09-01 上海奥博生物医药技术有限公司 一种福沙匹坦磷酸酯中间体的制备方法
CN106565783A (zh) * 2016-11-08 2017-04-19 山东裕欣药业有限公司 福沙匹坦双葡甲胺晶体化合物及其制备方法、药物组合物
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN109608498A (zh) * 2018-12-25 2019-04-12 四川制药制剂有限公司 一种福沙匹坦超临界反应制备方法
US11654154B2 (en) 2019-01-29 2023-05-23 Navinta Iii Inc Process for preparing injectable Fosaprepitant Dimeglumine compositions having improved storage stability
CA3173697A1 (en) 2020-04-03 2021-10-07 Mike TROWER An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
BR112022024208A2 (pt) 2020-06-02 2022-12-20 Nerre Therapeutics Ltd Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
AR051475A1 (es) * 2004-11-05 2007-01-17 Merck & Co Inc Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico

Also Published As

Publication number Publication date
EP2303901B1 (en) 2015-09-23
US8623844B2 (en) 2014-01-07
EP2303901A4 (en) 2012-07-18
WO2010018595A2 (en) 2010-02-18
ES2550003T5 (es) 2018-08-22
EP2303901B2 (en) 2018-05-09
CA2730681C (en) 2017-03-07
CA2730681A1 (en) 2010-02-18
WO2010018595A3 (en) 2011-05-26
US20110130366A1 (en) 2011-06-02
EP2303901A2 (en) 2011-04-06
EP2303901B8 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
ES2550003T3 (es) Producto intermedio de dimeglumina de fosaprepitant, fosaprepitant neutro y dimeglumina de fosaprepitant amorfa, y procesos para sus preparaciones
ES2395304B1 (es) Procedimiento de obtención de una tiofen-2-carboxamida.
CA2549062C (en) Novel oxazolidinone derivatives
CY1119827T1 (el) Ακυλαμινο-υποκατεστημενα συντηγμενα παραγωγα κυκλοπεντανο καρβοξυλικου οξεος και η χρηση αυτων ως φαρμακευτικων ουσιων
AR107474A2 (es) Proceso para la preparación de un ácido de 1,2,4-oxadiazol benzoico
ECSP099817A (es) Procesos para la preparacion de pirazoles
PE20121440A1 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos
CR9221A (es) Procesos para preparar eteres aromaticos
AR098260A2 (es) Polimorfo cristalino de una sal de bisulfato de un antagonista del receptor de trombina, proceso para su preparación, composición y forma purificada
UY30228A1 (es) Compuestos quimicos
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
BR112014014148A2 (pt) misturas de ácidos difosfínicos e dialquilfosfínicos, processo para produção das mesmas e uso das mesmas
KR20120016626A (ko) 티아졸 유도체들 및 ｐ2ｙ12 수용체 길항제로서 이들의 용도
WO2008123014A1 (ja) スルホン酸ｔｅｒｔ－ブチルフェニル化合物及びそれを用いたリチウム二次電池用非水電解液、並びにそれを用いたリチウム二次電池
Wang et al. Transition metal-free base-promoted arylation of sulfenate anions with diaryliodonium salts
AR079662A1 (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
RU2008130902A (ru) Способ получения пиколинатбориновых сложных эфиров
CR11578A (es) Derivados de oxadiazol activos e 1-fosfato de esfingosina
AR064465A1 (es) Procesopatra preparar (1r, 2s, 5s) -n- [(1s)]-3- amino-1- ( ciclobutimetil) -2,3- dioxopropil] -3- [2s)-2- [[[(1,1- dimetiletil) amino]- carbonil] amino ]-3,3- dimetil -1- oxobutil] 6,6- dimetil-3- azabicoiclo (3.1.0] hexan -2- carboxamida
CN103965185B (zh) 含有噻唑基和酯基的1,5-苯并二氮杂卓化合物及其应用
TW200718673A (en) Process for producing aromatic sulfonic acid compound
ES2655062T3 (es) Compuesto intermedio para la preparación de rosuvastatina cálcica y procedimiento para la preparación de rosuvastatina cálcica a partir del mismo
CN104837822B (zh) 含氟原子的巯基化合物
IL278644B2 (en) A process for the stereoselective preparation of chiral 2-[(hetero)aryl-alkyl-sulfanyl]-pyrimidines and products obtained from them